Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.
about
New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesThe phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activationEffects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids.Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids.Synthetic genistein derivatives as modulators of glycosaminoglycan storage.The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.Gene expression-targeted isoflavone therapy.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapiesGenistein supplementation in patients affected by Sanfilippo disease.Cyclodextrin encapsulation of daidzein and genistein by grinding: implication on the glycosaminoglycan accumulation in mucopolysaccharidosis type II and III fibroblasts.Sanfilippo syndrome: Overall review
P2860
Q28068142-CD25E840-D7C8-4D19-B625-F0FAD81336CFQ33761283-B3BDC716-651D-4BB7-92F7-F7C7DBF49200Q34626878-1BD29C1B-CDDF-415B-9E0F-367302134D04Q35206289-2A328BB0-6A37-4DAA-9B9C-F0A44AE23C0FQ36030017-4A383692-FA0E-47BF-9E93-7102C13245C4Q36232973-B42D5444-9A06-45F4-ADF5-38F5BAE608F9Q36433464-7F904F59-BF45-43A0-88DF-BB8F74B96F84Q37876354-526DA6B8-980F-4ABB-ABEF-CE14C1A1D085Q37987877-B18BD61F-A5DC-468D-9FF0-D1B586883162Q38040710-6E2B663F-A3CA-433F-BDE9-F896A95CD8A2Q39008165-A021E1F1-014D-4FAE-A238-6E0A2A255B35Q39060517-1E4F2818-D624-4E57-96A4-56815F5B3F93Q41977743-F32904C4-442E-4F55-A4D2-8D51CA6B5E59Q48674391-6051E3D3-9723-47F2-8B3D-659D633D102DQ49714390-F61F02DA-4125-4567-9D92-55EEEDCC83A7Q55982292-1D8D417D-C5CA-408E-8595-DBD400894117
P2860
Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Storage correction in cells of ...... nistein and other isoflavones.
@ast
Storage correction in cells of ...... nistein and other isoflavones.
@en
Storage correction in cells of ...... nistein and other isoflavones.
@nl
type
label
Storage correction in cells of ...... nistein and other isoflavones.
@ast
Storage correction in cells of ...... nistein and other isoflavones.
@en
Storage correction in cells of ...... nistein and other isoflavones.
@nl
prefLabel
Storage correction in cells of ...... nistein and other isoflavones.
@ast
Storage correction in cells of ...... nistein and other isoflavones.
@en
Storage correction in cells of ...... nistein and other isoflavones.
@nl
P2093
P1476
Storage correction in cells of ...... nistein and other isoflavones.
@en
P2093
Audrey Arfi
Christelle Gandolphe
Daniel Scherman
Magali Richard
P2860
P2888
P356
10.1007/S10545-009-9029-2
P577
2010-02-01T00:00:00Z
P6179
1005029482